Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AACR 2016 /
Normal and neoplastic stem cells

16th - 20th Apr 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 26.04.16
Views: 2447

Prof Irving L Weissman - Stanford University School of Medicine, Stanford, USA

Professor Irving L Weissman talks to ecancertv at AACR 2016 about his labs research into immune evasion of cancer cells.

Calreticulin, which is normally down-regulated by stem cells transiting between bone marrow sites, is also blocked from the surface of cancer stem cells to prevent immune recognition.

Normally, calreticulin acts as an “eat me signal” to macrophages, and by producing a humanised antibody towards it in treating leukaemia and solid tumours, Prof Weissman hopes to combine it with immunotherapeutics and recruit an immune response.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation